Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

SGLT2 inhibitors – a cautionary tale

April 19th 2016

SGLT2 inhibitors have been rapidly taken up due to their ideal properties of lowering blood glucose with accompanying weight loss, a positive impact on blood pressure and the fact that they do not cause hypoglycaemia. In fact, despite only being launched in 2012, they have been justified as a second line agent by NICE.

However, not long after launch, anecdotal evidence emerged regarding the potential association of diabetic ketoacidosis (in particular euglycaemic ketoacidosis) with the drugs – possibly as a result of reducing insulin doses or elevated glucagon levels. Whilst being licensed for treatment in Type 2 Diabetes, their insulin independent mode of action has resulted in them being used in some patients with Type 1 Diabetes. By May 2015, the fact that approximately 100 cases had been reported, lead to a review by the European Medicines Agency (EMA). As a result of these cases, the EMA has recommended updating the product information of SGLT2 inhibitors to list diabetic ketoacidosis as a rare adverse reaction (affecting up to 1 in 1,000 patients). Furthermore, it is advised that patients are counselled about the symptoms of DKA. There is a firming up of the licence regarding their specific use in T2DM only. However, it is increasingly recognised that patient do not always obligingly fit nicely into a diagnosis of T1 or T2, with some patients having a slow onset of T1 – now recognised in the NICE T1DM guidance. Advice is given regarding these and other patients who have risk factors for ketoacidosis. These include low insulin producing capacity in the pancreas and increased insulin requirement such as due to illness or alcohol abuse as well as conditions linked with reduced food intake or dehydration. In addition, EMA recommends temporarily stopping SGLT2 inhibitors in patients who are undergoing major surgery or are in hospital due to serious illness.

Whilst the benefit of SGLT2 inhibitors outweighs the risks, this guidance is a cautionary tale. Following their rapid uptake, it has not been the first time that a new class of diabetes drug has received caution following launch.

Dr Mark Freeman

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Napp DiabetesNovo NordiskBoehringer IngelheimAstraZeneca

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership